<DOC>
	<DOC>NCT02739711</DOC>
	<brief_summary>Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.</brief_summary>
	<brief_title>Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients With Myocardial Infarction and No-reflow</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>STelevation myocardial infarction and nonSTelevation myocardial infarction &lt;48 h after symptom onset Angiographic evidence of noreflow (Thrombolysis in Myocardial Infarctionflow grade ≤2) after primary percutaneous coronary intervention Age ≥18 years Informed consent STelevation myocardial infarction and nonSTelevation myocardial infarction patients with Thrombolysis in Myocardial Infarctionflow 3 after primary percutaneous coronary intervention Age ≤18 years Known pregnancy, breastfeeding or intend to become pregnant during the study period Contraindication for treatment with platelet inhibitors Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin Active peptic gastric or duodenal ulcer History of major surgery (including intracranial or intraspinal) &lt;4 weeks Active bleeding or bleeding diathesis Stroke &lt;2 years (ischemic and hemorrhagic) Known coagulation defect or relevant thrombocytopenia Arteriovenous malformations or aneurysm Severe liver insufficiency Renal insufficiency requiring dialysis Uncontrolled hypertension Hypertensive retinopathy Vasculitis Fibrinolysis &lt;12 hours Contraindication for cardiac magnetic resonance imaging at study entry Patients without informed consent Participation in another trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>